Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
4.780 ^USD	-4.40%		+2.36%	-12.58%

05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
05-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

Published on 03/12/2026 at 08:07 pm GMT

S&P Capital IQ

BOLT BIOTHERAPEUTICS, INC.

-4.40%

Bolt Biotherapeutics, Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported net loss was USD 33.38 million compared to USD 63.12 million a year ago. Basic loss per share from continuing operations was USD 17.85 compared to USD 33.06 a year ago.

Latest news about Bolt Biotherapeutics, Inc.

05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
05-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-11	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-22	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE
01-15	Bolt appoints Olta Andoni as SVP of legal and people to support platform expansion across checkout, identity, and payments	RE
11-12	Bolt Biotherapeutics Q3 collaboration revenue doubles	RE
11-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
02/10/25	Bolt Biotherapeutics, Inc. Announces Reduction of its Current Workforce by Approximately 20 Employees, or Approximately 50% of its Workforce	CI
02/10/25	Bolt Biotherapeutics, Inc. Provides Update on Ongoing Phase 1 Dose Escalation Study of BDC-4182	CI
02/10/25	Washington Shutdown Continues as US Equity Futures Trade Mixed Ahead of Opening Bell	MT
02/10/25	Top Premarket Decliners	MT
01/10/25	Bolt Biotherapeutics to Cut Workforce by 50%; Cancer Drug Trial Data Expected in Q3 of 2026	MT
01/10/25	Bolt Biotherapeutics Provides Update on BDC-4182	CI
14/08/25	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

Chart Bolt Biotherapeutics, Inc.

Duration

Period

BOLT: Dynamic Chart

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Companyâ€™s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Companyâ€™s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees

Sector

Biotechnology & Medical Research

More about the company